Increased Intrathecal High-Avidity Anti-Tau Antibodies in Patients with Multiple Sclerosis
Figure 2
Avidities of CSF and serum anti-tau antibodies.
A. Avidity of anti-tau antibodies in serum. There was no difference between the totals MS patients and controls. The patients in RR-rMS and SPMS subgroups had significantly higher serum anti-tau avidities in comparison with RR-aMS (RR-rMS vs. RR-aMS: p<0.01; SPMS vs. RRaMS: p<0.01). The serum avidities in RR-aMS were slightly lower than those in the control group (p<0.05). B. Avidity of anti-tau antibodies in CSF. Avidities of anti-tau IgG antibodies in CSF were significantly higher in the MS group as a whole than in the controls (p<0.05). There was also a significant difference in avidities between RR-rMS subgroup and the control group (p<0.05). The avidities of anti-tau antibodies in the CSF were significantly elevated in comparison with those in the serum in both the MS group and the controls (MS group: CSF vs. serum p<0. 0001; controls: CSF vs. serum p<0. 005). Compare corresponding box plots – MS (total) and controls between Fig. 2A and 2B. Abbreviations: CSF = cerebrospinal fluid; S = serum; other abbreviations are explained in the Fig. 1.